Transforming the prevention of pregnancy complications

Pregnancy complications affect approximately 25% of pregnancies, with preeclampsia being one of the main causes of maternal and neonatal morbidity.

Despite its clinical impact, current screening strategies present significant limitations:

Non-standardised protocols

Subjective, operator-dependent assessment

Limited capacity to allow effective preventive intervention

There is a significant unmet clinical need in obstetrics.

The clinical challenge: detecting before the disease appears

Preeclampsia is a multisystem disorder characterised by new-onset hypertension and organ dysfunction..

The main challenge is not its treatment, but detection in preclinical stages, when intervention can modify the course of the disease.

Biological origin: failure in embryo implantation

Our research has identified a key mechanism in the origin of preeclampsia:
Resistance to endometrial decidualisation

Alteration in the differentiation of the endometrium
Dysfunction in implantation and placental development
Associated with altered transcriptomic profiles
Linked to a dysregulated immune response

This process generates a molecular signature detectable in maternal blood through cfRNA.

Our solution: MaiRa

First-trimester preeclampsia risk assessment based on:

Maternal blood sample

Taken between weeks 9 and 14

Molecular analysis

Extraction of circulating cell-free RNA from plasma and analysis with massive sequencing (NGS)

Interpretation of results

Individual risk prediction with an AI-based algorithm from proprietary medical software

Report

Results to support medical decisions

This approach makes it possible to move from the observation of symptoms to prediction based on molecular biology.

Clinical advantages

MaiRa allows an early risk assessment:

Sample collection: weeks 9–14

Up to 18 weeks ahead of the appearance of symptoms

Assessment based on molecular biology (not on clinical manifestations)

Simple clinical workflow (no need for complex additional tests)

Compatible with NIPT (same blood sample)

Clinical value

Early identification of risk makes it possible to:

Risk stratification

Preventive intervention

Personalised monitoring

Expected clinical impact

Impact on clinical practice

For the patient

For the specialist

For the healthcare system

Scientific evidence

MaiRa is born from a scientific approach designed to transform prenatal diagnosis, shifting the detection of complications from the appearance of symptoms towards the early identification of biological signals.

Through the PREMOMclinical study, we have identified an early molecular signal based on cfRNA and developed a predictive model capable of anticipating the risk of preeclampsia before its clinical manifestation. This work has laid the foundations for a new approach in maternal-fetal medicine, backed by high-impact scientific publications.

The iPregnosticstudy, currently ongoing, represents the next step: to validate, scale and consolidate this model in real clinical practice, reinforcing its robustness and its potential as a standard in early pregnancy screening.